Biotechnology

Biovica Announces the Start of a DiviTum(R) TKa Clinical Trial

August 24, 2023 4:50 AM

UPPSALA, SWEDEN / ACCESSWIRE / August 24, 2023 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer diagnostics, today announces the initiation of a prospective clinical trial to study the correlation between DiviTum TKa levels and the effects of medication dose reductions in the care of metastatic breast cancer patients. "We are very proud to be partnering with Yale on such an important prospective study. If...

Read more

Qrons Announces Launch of its New Website in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis

August 23, 2023 9:35 AM

NEW YORK, NY / ACCESSWIRE / August 23, 2023 / Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products treatments and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the launch of its updated website at www.qrons.com. This update will provide investors and the public an overview of the company's strides in dealing with infectious disease...

Read more

AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of PREVYMIS(R) (letermovir) in Second Indication

August 23, 2023 8:15 AM

PREVYMIS ® now approved for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R‑]) This first-in-class antiviral agent was initially approved by FDA for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT) AiCuris received Euro €30 Million milestone payment and...

Read more

Enalare Therapeutics Selected to Present at Three Upcoming Scientific Conferences Regarding Its Lead Compound, ENA-001

August 22, 2023 9:00 AM

PRINCETON, NJ / ACCESSWIRE / August 22, 2023 / Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life- threatening critical care diseases and community health emergencies, announced today that it has been chosen to present at three prestigious scientific conferences in the upcoming months: PAINWeek, American Society for Enhanced Recovery and Perioperative Medicine...

Read more

Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer

August 22, 2023 8:00 AM

NORTH PALM BEACH, FL / ACCESSWIRE / August 22, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in the therapeutic monoclonal antibody space, announced today that the Company has been cleared by the FDA to begin Phase II clinical trials for brain cancer. This milestone allows the Company to continue advancing Pritumumab through the...

Read more

Genomes.io Secures a $20 Million Commitment From GEM Digital Limited

August 21, 2023 4:00 AM

Genomes.io's $20 million financial commitment will assist the company in its mission to make the genomics market more equitable and transparent for all involved. LONDON, UK / ACCESSWIRE / August 21, 2023 / Genomes.io, a biotech company focused on the safe, private, and auditable monetization of genomic data, has today revealed its partnership with the Bahamas-based digital asset investment firm GEM Digital Limited. The $20m financial commitment...

Read more

Amber Ophthalmics Announces First Patient Enrolled in NEXPEDE-1, a Phase 2/3 Clinical Trial Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defects

August 18, 2023 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / August 18, 2023 / Amber Ophthalmics, Inc. (Amber), a privately held, clinical stage biopharmaceutical company, announced today that Dr. Mark S. Gorovoy from Gorovoy M.D. Eye Specialists has enrolled the first patient in the AMB-01-006 (NEXPEDE-1) study. The NEXPEDE-1 study is a randomized, double-masked, vehicle-controlled Phase 2/3 clinical trial designed to evaluate two concentrations of Nexagon® (lufepirsen...

Read more

WholisticResearch Reveals the Best Nootropics of 2023

August 17, 2023 1:25 PM

In-depth Analysis and Testing Unveil the Leading Brain-Boosting Supplements LONDON, ENGLAND / ACCESSWIRE / August 17, 2023 / WholisticResearch, a leading authority in the realm of cognitive enhancement research, has recently unveiled its list of the top nootropic supplements for 2023. Following rigorous testing and comprehensive analysis, the organization has identified the most effective cognitive enhancers available on the market today....

Read more

Inherent Biosciences, Inc. Advances Fertility Solutions With Transformative Grant Funding From the NIH

August 17, 2023 10:38 AM

A Leap Forward for Patients, a Promising Opportunity for Investors, and a Revolutionary Tool for Physicians SALT LAKE CITY, UT / ACCESSWIRE / August 17, 2023 / Inherent Biosciences, Inc., a commercial-stage life science company, is at the forefront of innovation with its epigenetic diagnostic tools designed to enhance and support the reproductive journey. The company has secured a $1.9 million Fast-Track SBIR grant from the National Institutes...

Read more

M2bio Sciences Announces Launch of Exclusive MMA Organization

August 17, 2023 10:15 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / August 17, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES) ("Institute of Biomedical Research" or the "Company"), a pioneering force in nutraceutical biotechnology specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research powered by artificial intelligence, takes immense pride in presenting its latest development: M2Bio...

Read more

Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

August 17, 2023 8:00 AM

BOSTON, MA / ACCESSWIRE / August 17, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals. The milestone is based on dosing the first patient in a Boston Pharmaceutical-sponsored...

Read more

Cantabio Pharmaceuticals Receives Additional Grant from The Michael J. Fox Foundation for Testing Its Novel Redox DJ-1 Protein-based ELISA Platform for the Diagnosis of Parkinson's Disease

August 17, 2023 2:20 AM

Grant enables the application of Cantabio's Redox DJ-1 ELISA platform for the quantification of specific oxidized states of DJ-1 in Parkinson's disease patients' bio-samples, such as iPSC-derived dopaminergic neurons, post-mortem brain tissue and plasma, for the development of a new biomarker potentially for early diagnosis of and tracking the progression of Parkinson's disease SAN MATEO, CA / ACCESSWIRE / August 17, 2023 / Cantabio...

Read more

EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic

August 16, 2023 9:30 AM

TAMPA, FL / ACCESSWIRE / August 16, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has completed production of a next-generation, "Gen-2", MSC exosome-based therapeutic product. Rigorous product analysis has already begun, and the Company has engaged leading independent testing laboratories to perform sophisticated analyses of molecular composition, therapeutic activity, and any potential forms of contamination, to thoroughly...

Read more

Native Cardio Inc. Welcomes Steve Adler as New CEO — Medical Device Company Poised to Enter the Atrial Fibrillation Market

August 16, 2023 8:00 AM

NAPLES, FL / ACCESSWIRE / August 16, 2023 / Native Cardio Inc. announced today that Steve Adler has agreed to join the company as Chief Executive Officer. Native's first product, the Rhythm Maker™ system, is designed to provide low-energy electrical pulses to convert postoperative atrial fibrillation (POAF) to normal sinus rhythm. The system is intended for hospitalized patients who have undergone cardiac surgery. Approximately 40% of all...

Read more

AbTherx Appoints Gavin Thurston, PhD, as Scientific Advisor

August 16, 2023 6:00 AM

Former Regeneron Oncology Leader Joins AbTherx to Advance its Antibody Discovery Platform MOUNTAIN VIEW, CA / ACCESSWIRE / August 16, 2023 / AbTherx, a privately held biotech company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of Gavin Thurston, PhD, as a scientific advisor. In his new role, Dr. Thurston will provide counsel on the Company's research, development, and product...

Read more

Biophytis Announces Next Regulatory Steps in Europe and the United States for its COVA Project

August 16, 2023 1:15 AM

PARIS FRANCE and CAMBRIDGE, MA / ACCESSWIRE / August 16, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, announced today that it has received feedback from the European...

Read more

Hoag Hospital and Imagene Partner to Empower Rapid Cancer Diagnosis for Personalized Cancer Care

August 15, 2023 8:00 AM

Leveraging AI-based molecular profiling from a digitized biopsy image to enable physicians to gain immediate oncology intelligence. NEWPORT BEACH, CA / ACCESSWIRE / August 15, 2023 / Hoag, the largest community-based healthcare system in southern California, and Imagene, an emerging leader in the field of AI-based precision oncology, are pleased to announce their strategic collaboration aimed at transforming molecular diagnosis and advancing...

Read more

Form Bio Announces Executive Webinar Featuring BCG, ElevateBio, and NVIDIA

August 15, 2023 7:49 AM

Data Science Meets Life Science: AI Challenges & Opportunities in Biopharma, Synthetic Biology and Beyond DALLAS, TX / ACCESSWIRE / August 15, 2023 / Form Bio, the breakthrough computational life sciences platform, is hosting an executive webinar on exploring AI challenges and opportunities in biopharma, synthetic biology, and more. WHEN: Tuesday, September 5, 2023 at 10 a.m. PST WHERE: Register and attend online for the Data Science Meets...

Read more

Longwood Healthcare Leaders to Convene Top Biotech and Pharmaceutical Leaders and Researchers

August 15, 2023 7:00 AM

BOSTON, MA / ACCESSWIRE / August 15, 2023 / Longwood Fund, an early-stage life science venture firm, will convene top biopharmaceutical leaders for two days of off-the-record discussions and networking at its Fall Longwood Healthcare Leaders Conference, co-hosted by Harvard Medical School Dean, George Daley, at Harvard Medical School's Joseph B. Martin Conference Center, September 18-19, 2023. The industry-leading conference focuses on a broad...

Read more

Qrons Announces the Filing of a Provisional Patent Application in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis

August 14, 2023 11:30 AM

NEW YORK, NY / ACCESSWIRE / August 14, 2023 / Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the filing on August 9, of a United States Provisional Patent Application entitled Tellurium Compositions and Techniques For Use Therewith. This filing is in furtherance of its Neuronal and Infectious...

Read more